Home » Biosite Announces FDA Clearance to Market Triage TOX
Biosite Announces FDA Clearance to Market Triage TOX
Biosite, a research-based provider of novel, rapid medical diagnostics, has announced that the FDA has granted the company clearance to market the Triage TOX Drug Screen with Acetaminophen (APAP), the first drug screen to include a rapid, point-of-care test for the qualitative detection of acetaminophen in urine.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/03-02-2005/0003112205&EDATE=)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct